{"slug":"tirzepatide-glp1-agonists","verification":{"valid":true,"entries":14,"head":"8ba1f9ededee061d98c9bc2bed19865f8af0c3a9aed982fb3014474fa07967a1"},"count":14,"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40746703/","title":"Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration","quote":"A dose-dependent tirzepatide was superior to placebo and GLP-1 RAs in weight reduction. However, the lean mass reduction and tolerability require further investigation.","summary":"2025 meta-analysis of 6 RCTs (6266 subjects) showing tirzepatide (5-15mg) superior for weight loss vs placebo/GLP-1 RAs; high-certainty for ≥15% loss.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:45:36.162Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"0bc10e667490a0d1de52db56c7f9bc6edd4628dab777683966ad8fb5aa31ffbe"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42119587/","title":"Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial","quote":"We evaluated the efficacy and safety of continuing tirzepatide at the maximum tolerated dose (MTD) or lowering the dose to 5 mg compared with placebo.","summary":"2026 Lancet phase 3 trial on tirzepatide for weight maintenance in obesity.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:45:36.162Z","link_status":"ok","quote_status":"unverified","prev":"0bc10e667490a0d1de52db56c7f9bc6edd4628dab777683966ad8fb5aa31ffbe","hash":"8f9696ced4d3722d12ef2047cdc36535115e6cec92eb6498ecc410a89fc2c0fc"},{"id":"s3","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT06820281","title":"Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes","quote":"This mechanistic study will define mechanisms by which GLP1-GIP co-agonism may uniquely provide clinical benefits in T1D during the fasting and fed states.","summary":"2025 mechanistic trial on tirzepatide (GLP-1/GIP agonist) effects in type 1 diabetes.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:45:36.162Z","link_status":"ok","quote_status":"unverified","prev":"8f9696ced4d3722d12ef2047cdc36535115e6cec92eb6498ecc410a89fc2c0fc","hash":"167a284b48b2506597dcd0895fe37a97fc5a85d7d4f10fc652f45ef99360643e"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40353578/","title":"Tirzepatide as Compared with Semaglutide for the Treatment of Obesity","quote":"Among participants with obesity but without diabetes, treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight.","summary":"2025 SURMOUNT-5 trial: tirzepatide superior to semaglutide for weight loss in obesity without diabetes.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:45:36.162Z","link_status":"ok","quote_status":"unverified","prev":"167a284b48b2506597dcd0895fe37a97fc5a85d7d4f10fc652f45ef99360643e","hash":"3fcae7a5d9dce8b01400f3fddfd4cf2af5d76d57cb7e347371a7489bb63d625b"},{"id":"s5","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41264593/","title":"Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Clinical Trial","quote":"Among adults with type 1 diabetes and obesity, tirzepatide was superior to placebo for weight loss over 12 weeks.","summary":"2026 phase 2 trial showing tirzepatide benefits in T1D with obesity.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:45:36.162Z","link_status":"ok","quote_status":"verified","prev":"3fcae7a5d9dce8b01400f3fddfd4cf2af5d76d57cb7e347371a7489bb63d625b","hash":"3d44a8cc318c688eecec61496d7e0d2383560fd7f27b5d7e4e7227a9900a2699"},{"id":"s6","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/41761267/","title":"Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis","quote":"These findings suggest that tirzepatide provides cardiovascular benefit at least comparable to established GLP-1RAs, supporting its emerging role in cardiovascular risk reduction in T2D.","summary":"Systematic review and network meta-analysis of RCTs showing tirzepatide reduces MACE, CV mortality, all-cause mortality, non-fatal MI and stroke vs placebo, comparable to GLP-1RAs.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:45:53.437Z","link_status":"ok","quote_status":"verified","prev":"3d44a8cc318c688eecec61496d7e0d2383560fd7f27b5d7e4e7227a9900a2699","hash":"8ee4366358b7274f085aa6b39475f0e69642e72bd24b4f5825e4f569c83da422"},{"id":"s7","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42168641/","title":"Causes and consequences of discontinuation of GLP1RAs and tirzepatide","quote":"In this Review, we discuss common reasons for GLP1R agonist and tirzepatide discontinuation and examine available evidence related to potential cardiometabolic ...","summary":"Review on discontinuation reasons for GLP-1RAs including tirzepatide and cardiometabolic evidence.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:45:53.437Z","link_status":"ok","quote_status":"unverified","prev":"8ee4366358b7274f085aa6b39475f0e69642e72bd24b4f5825e4f569c83da422","hash":"0371dcd0b18e6afd6695db514160cfd9aa4c24c546e658dc2ae6a5321560e678"},{"id":"s8","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41655764/","title":"Ocular Outcomes with Tirzepatide versus Glucagon-like Peptide-1 Receptor Agonists","quote":"Among patients with T2D taking a GLP-1 RA, tirzepatide was associated with lower risks of retinal complications, need for vision-saving ...","summary":"Study finding lower retinal complication risks with tirzepatide vs other GLP-1 RAs in T2D patients.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:45:53.437Z","link_status":"ok","quote_status":"unverified","prev":"0371dcd0b18e6afd6695db514160cfd9aa4c24c546e658dc2ae6a5321560e678","hash":"f48a6b4930245e0cbba1fa071ffd6911cb87d527571210dc93b88f65ff1cae64"},{"id":"s9","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41936548/","title":"Weight Loss With GLP-1 Agonists in Nondiabetic Adults","quote":"Tirzepatide, particularly at higher doses, provides the greatest weight reduction in adults without diabetes.","summary":"Analysis showing tirzepatide superior for weight loss in nondiabetic adults compared to other GLP-1 agonists.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:45:53.437Z","link_status":"ok","quote_status":"verified","prev":"f48a6b4930245e0cbba1fa071ffd6911cb87d527571210dc93b88f65ff1cae64","hash":"d7ea3b96d9412a96a0034ce9dee3ef7ee725221cd2174c0d90daf51b66336bbd"},{"id":"s10","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39536238/","title":"Tirzepatide for Obesity Treatment and Diabetes Prevention","quote":"Three years of treatment with tirzepatide in persons with obesity and prediabetes resulted in substantial and sustained weight reduction and a markedly ...","summary":"Clinical trial on long-term tirzepatide effects for obesity and preventing diabetes.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:46:46.649Z","link_status":"ok","quote_status":"unverified","prev":"d7ea3b96d9412a96a0034ce9dee3ef7ee725221cd2174c0d90daf51b66336bbd","hash":"618dbdfb4a58bbfeece27a15d8f5f22dacaa99179032831cfe327a926552ef81"},{"id":"s11","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39996368/","title":"Real-world use and effectiveness of tirzepatide among ...","quote":"To understand real-world tirzepatide utilization and effectiveness (change in weight and body mass index [BMI]) among people without type 2 diabetes (T2D) in ...","summary":"Real-world evidence on tirzepatide for weight loss in non-T2D patients.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:46:46.649Z","link_status":"ok","quote_status":"unverified","prev":"618dbdfb4a58bbfeece27a15d8f5f22dacaa99179032831cfe327a926552ef81","hash":"90ba4559e112441e16ccab0ad829ecf3b5531ea4a58b2b367ba749c98a97158f"},{"id":"s12","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41354867/","title":"A real-world study of tirzepatide for weight loss in adults ...","quote":"In this prospective multicentre observational study, 115 adults with obesity but without diabetes were treated with tirzepatide 2.5 mg weekly for 4 weeks, ...","summary":"Observational study on tirzepatide weight loss in obese non-diabetics.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:46:46.649Z","link_status":"ok","quote_status":"unverified","prev":"90ba4559e112441e16ccab0ad829ecf3b5531ea4a58b2b367ba749c98a97158f","hash":"f4c11038e72ab8c7005b3dfab969991d09b0e4ce55a438ceb70fd3f151a59f60"},{"id":"s13","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40630338/","title":"Dose-Dependent Efficacy and Safety of Tirzepatide for ...","quote":"Tirzepatide produces substantial, dose-dependent weight loss and improves metabolic and quality-of-life outcomes in obese adults without diabetes.","summary":"Meta-analysis of RCTs on dose-dependent effects in non-diabetic obesity.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:46:46.649Z","link_status":"ok","quote_status":"verified","prev":"f4c11038e72ab8c7005b3dfab969991d09b0e4ce55a438ceb70fd3f151a59f60","hash":"aabf05417b19dead08fb2ddc2854fc38b8b839bdf3cbe541dc38c830af7377a9"},{"id":"s14","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41196501/","title":"Insights into the Mechanism of Action of Tirzepatide","quote":"Here, we review the mechanistic activity of tirzepatide and its effect on glycemic control, body weight, the cardiorenal system, and lipid metabolism.","summary":"Narrative review on tirzepatide mechanisms as dual GIP/GLP-1 agonist.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T17:46:46.649Z","link_status":"ok","quote_status":"verified","prev":"aabf05417b19dead08fb2ddc2854fc38b8b839bdf3cbe541dc38c830af7377a9","hash":"8ba1f9ededee061d98c9bc2bed19865f8af0c3a9aed982fb3014474fa07967a1"}]}